Welcome to BeiMedPlus

Dr Riyaz Shah discusses alternative PD-1 inhibitors as the backbones for immunotherapy combinations.

Dr Ross Soo addresses why we need another PD-1/PD-L1 inhibitor. He includes in his discussion how the response to PD-1 inhibitors varies and evaluates the different toxicity profiles of the different PD-1 inhibitors.

Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.